Molecular therapy in myotonic dystrophy: focus on RNA gain-of-function

• Published in: Human molecular genetics Vol. 19; no. R1; pp. R90 - R97
• Main Authors: Mulders, Susan A.M., van Engelen, Baziel G.M., Wieringa, Bé, Wansink, Derick G.
• Format: Journal Article
• Language: English
• Published: England Oxford University Press 15-04-2010
• Subjects: Humans; Myotonic Dystrophy - drug therapy; Myotonic Dystrophy - genetics; Myotonin-Protein Kinase; Protein Binding; Protein-Serine-Threonine Kinases - genetics; RNA Interference; RNA, Messenger - genetics; RNA-Binding Proteins - genetics
• ISSN: 0964-6906; 1460-2083
• DOI: 10.1093/hmg/ddq161

Myotonic dystrophy (DM) is a complex, dominantly inherited, multisystem disorder and the archetypal example of an RNA gain-of-function disease. Unstable expansions of (CTG•CAG)n or (CCTG•CAGG)n repeat tracts in the DMPK and ZNF9 genes cause the two known subtypes of myotonic dystrophy, DM1 and DM2, for which no cure or effective molecular treatment exists. Focus in therapeutic development is currently on toxic, expanded (C/CUG)n RNAs. A series of recent papers provide proof of concept of promising strategies using antisense oligonucleotides or small organic compounds aimed at either complete elimination of expanded (CUG)n RNA transcripts or prevention of detrimental protein binding to thermodynamically stable (C/CUG)n hairpin structures. These developments offer new hope to patients with DM, even though several hurdles still have to be overcome before they can be introduced into clinical practice.